Trial
NCT04248465
An Efficacy and Safety Study of Ravulizumab in ALS Participants
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Amyotrophic Lateral Sclerosis
Intervention
Placebo
Why stopped
The IDMC recommended the study be discontinued due to lack of efficacy with ravulizumab.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-01-10